BRPI1015424A2 - métodos e composições utilizando peptídeos e proteínas com elementos de terminação c. - Google Patents

métodos e composições utilizando peptídeos e proteínas com elementos de terminação c.

Info

Publication number
BRPI1015424A2
BRPI1015424A2 BRPI1015424-8A BRPI1015424A BRPI1015424A2 BR PI1015424 A2 BRPI1015424 A2 BR PI1015424A2 BR PI1015424 A BRPI1015424 A BR PI1015424A BR PI1015424 A2 BRPI1015424 A2 BR PI1015424A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
proteins
peptides
interest
Prior art date
Application number
BRPI1015424-8A
Other languages
English (en)
Inventor
Teesalu Tambet
Ruoslahti Erkki
Sugahara Kazuki
Original Assignee
Burnham Institute For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Institute For Medical Research filed Critical Burnham Institute For Medical Research
Publication of BRPI1015424A2 publication Critical patent/BRPI1015424A2/pt
Publication of BRPI1015424B1 publication Critical patent/BRPI1015424B1/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)

Abstract

métodos e composições utilizando peptídeos e proteínas com elementos de terminação c são revelados composições e métodos úteis para alvejamento e internalização de moléculas em células de interesse e para penetração por moléculas de tecidos de interesse. as composições e métodos são baseados nas sequências de peptídeo que são seletivamente internalizadas por uma célula,penetram o tecido ou ambas. a internalização revelada e penetração de tecido é útil para entrega terapêutica e agentes detectáveis para células e tecidos de interesse.
BRPI1015424-8A 2009-06-22 2010-06-22 Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição BRPI1015424B1 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21908609P 2009-06-22 2009-06-22
US61/219,086 2009-06-22
US61/219,140 2009-06-22
US24914009P 2009-10-06 2009-10-06
US61/249,140 2009-10-06
PCT/US2010/039539 WO2011005540A1 (en) 2009-06-22 2010-06-22 Methods and compositions using peptides and proteins with c-terminal elements

Publications (2)

Publication Number Publication Date
BRPI1015424A2 true BRPI1015424A2 (pt) 2019-04-16
BRPI1015424B1 BRPI1015424B1 (pt) 2022-01-18

Family

ID=42542888

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015424-8A BRPI1015424B1 (pt) 2009-06-22 2010-06-22 Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição

Country Status (8)

Country Link
US (4) US10370245B2 (pt)
EP (1) EP2445536B1 (pt)
JP (2) JP5906184B2 (pt)
KR (1) KR20120048563A (pt)
CN (1) CN102869384B (pt)
BR (1) BRPI1015424B1 (pt)
CA (1) CA2766634A1 (pt)
WO (1) WO2011005540A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
NZ591524A (en) 2004-10-07 2012-09-28 Transmedics Inc Method for timing pulsatile flow of normothermic perfusate to the heart in ex-vivo organ care
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US8642009B2 (en) * 2005-12-16 2014-02-04 Catherine M. Shachaf Diagnostic system for the detection of skin cancer
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US8420380B2 (en) 2008-01-31 2013-04-16 Transmedics, Inc. Systems and methods for ex vivo lung care
EP3569241A1 (en) 2010-02-26 2019-11-20 Vascular Biosciences, Inc. Car peptide for homing, diagnosis & targeted therapy for pulmonary and fibrotic disorders
CA2795289A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
EP2704560B1 (en) 2011-04-14 2022-04-06 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US20140024501A1 (en) * 2012-07-19 2014-01-23 Juan Cruz Tabena Isern Swimming training device
KR101551299B1 (ko) * 2013-05-23 2015-09-10 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
US10711275B2 (en) 2013-07-12 2020-07-14 Zhen Huang Methods and compositions for interference with DNA polymerase and DNA synthesis
US10076112B2 (en) 2014-06-02 2018-09-18 Transmedic, Inc. Ex vivo organ care system
CN107108743B (zh) * 2014-12-03 2021-05-04 (株)爱恩德生物 结合神经毡蛋白1的抗体及其用途
EP3031821A1 (en) * 2014-12-08 2016-06-15 Life Science Inkubator polyomavirus VLPs with a fusion protein
EP3031820A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
WO2016090498A1 (en) 2014-12-12 2016-06-16 Freed Darren Apparatus and method for organ perfusion
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
BR112017020948A2 (pt) * 2015-03-31 2018-07-10 Ildong Pharm Co., Ltd. composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
EP3124052A1 (de) 2015-07-30 2017-02-01 Albrecht Piiper Verfahren zur diagnose von karzinomen mittels irgd und magnetresonanztomographie (mrt)
RU2727238C2 (ru) * 2015-09-01 2020-07-21 Илдонг Фармасьютикал Ко., Лтд. Фармацевтическая композиция, содержащая в качестве активного ингредиента слитый белок, в котором слиты проникающий в опухоль пептид и антиангиогенное средство, для предупреждения и лечения рака или связанных с ангиогенезом заболеваний
EP3347084B1 (en) 2015-09-09 2020-11-11 Transmedics, Inc. Aortic cannula for ex vivo organ care system
RU2599462C1 (ru) * 2015-09-22 2016-10-10 Общество с ограниченной ответственностью "БИОТЕХНОЛОГИЯ" (ООО "БИОТЕХНОЛОГИЯ") Способ полисигнальной активации апоптоза клеток злокачественных солидных опухолей
CN105294841A (zh) * 2015-11-24 2016-02-03 中国人民解放军第四军医大学 基于CendR内化增效序列的放射性核素标记肿瘤靶向分子影像探针及其合成方法与应用
CA3025673A1 (en) 2016-05-30 2017-12-07 Tevosol, Inc. Apparatus and method for ex vivo lung ventilation with a varying exterior pressure
WO2017209553A2 (ko) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2017209554A2 (ko) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 항-nrp1 항체 스크리닝 방법
AU2017273169B2 (en) 2016-06-03 2020-07-30 Aimed Bio Inc. Method for screening antibody using patient-derived tumor spheroids
EP3467508A4 (en) 2016-06-03 2020-04-29 Samsung Life Public Welfare Foundation Anti-nrp1 antibody screening method
EP3354270A4 (en) * 2016-10-21 2019-04-24 Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya" METHOD FOR ACTIVATION OF APOPTOSIS OF CELLS WITH MULTIPLE SIGNALING OF SOLID MALIGNANT TUMORS
WO2018085050A1 (en) 2016-11-03 2018-05-11 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for imaging tissues and tumors
RU2656188C1 (ru) * 2017-05-03 2018-06-04 Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") Синтетическое анальгетическое средство пептидной природы и способ его применения
EP3642219A4 (en) * 2017-06-19 2021-06-09 Allegro Pharmaceuticals, LLC PEPTIDE COMPOSITIONS AND RELATED PROCEDURES
US12454549B2 (en) 2017-06-19 2025-10-28 Jenius Pharma, Llc Treatments for diseases and disorders that involve oxidative stress
ES3019687T3 (en) 2017-11-20 2025-05-21 Transmedics Inc Device and kit for supporting and connecting an excised organ
CN108676097B (zh) * 2018-05-24 2020-01-14 北京肽和生物科技有限公司 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用
CN108948149A (zh) * 2018-07-11 2018-12-07 江苏省原子医学研究所 一种68Ga标记的化合物及其制备的弗林酶靶向PET显像剂
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
WO2020139978A1 (en) * 2018-12-27 2020-07-02 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US12583888B2 (en) 2019-02-04 2026-03-24 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US12351653B1 (en) 2019-03-08 2025-07-08 Lisata Therapeutics, Inc. Pharmaceutical compositions comprising novel cyclic peptides
CN113795271A (zh) * 2019-03-08 2021-12-14 森德治疗公司 与irgd共施用以治疗癌症的低剂量细胞因子
US20230201303A1 (en) * 2020-05-04 2023-06-29 Drugcendr Australia Pty Ltd. Methods for treating pancreatic cancer and other solid tumors
US20230050515A1 (en) * 2021-05-04 2023-02-16 Cend Therapeutics, Inc. iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS
CN114555625B (zh) * 2019-07-02 2025-02-25 塔夫茨学院托管部 用于将剂递送至细胞和组织中的新型肽、组合物和方法
KR102176415B1 (ko) * 2019-08-02 2020-11-09 중앙대학교 산학협력단 원핵세포 투과성 재조합 단백질 및 이의 용도
US11436242B2 (en) 2019-09-20 2022-09-06 Fisher-Rosemount Systems, Inc. Edge gateway system with contextualized process plant knowledge repository
US11165839B2 (en) 2019-09-20 2021-11-02 Fisher-Rosemount Systems, Inc. Edge gateway system with data typing for secured process plant data delivery
US10915081B1 (en) * 2019-09-20 2021-02-09 Fisher-Rosemount Systems, Inc. Edge gateway system for secured, exposable process plant data delivery
WO2021207742A1 (en) 2020-04-10 2021-10-14 Mi2 Holdings LLC Nanoparticles for use in photodynamic therapies and methods of making, evaluating and using the same
EP3913370A1 (en) 2020-05-18 2021-11-24 Albrecht Piiper Method for diagnosing carcinomas using irgd as a tumor marker booster
CN115470810B (zh) * 2022-07-06 2025-07-11 杭州电子科技大学 一种基于扩散模型框架的脑电语义可视化方法
CN116251195B (zh) * 2022-12-27 2023-12-05 哈尔滨吉象隆生物技术有限公司 一种紫杉醇靶向肽偶联物及其应用
WO2025017349A1 (en) * 2023-07-18 2025-01-23 Hosseinkhani Saman Peptide-based dna vaccine platform
CN119019499B (zh) * 2024-10-30 2025-03-21 山东第二医科大学 一种促进乳腺癌细胞铁死亡的功能性载药小分子肽

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3556722A (en) 1966-09-24 1971-01-19 Furukawa Mining Co Process for treating sulfurous acid gas-containing exhaust gas
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5569745A (en) 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
AU703120B2 (en) 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6222654B1 (en) * 1997-08-04 2001-04-24 Lucent Technologies, Inc. Optical node system for a ring architecture and method thereof
US6723512B2 (en) * 1997-08-29 2004-04-20 Selective Genetics Inc. Methods using genetic package display for detecting and identifying protein-protein interactions that facilitate internalization and transgene expression and cells or tissues competent for the same and methods for evolving gene delivery vectors
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US20030148263A1 (en) 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
GB9825555D0 (en) * 1998-11-20 1999-01-13 Imp College Innovations Ltd Suppression of xenotransplant rejection
AU7572900A (en) * 1999-08-26 2001-03-19 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
CN101041079A (zh) 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU4801501A (en) 2000-05-26 2001-11-29 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
AU8524901A (en) 2000-08-25 2002-03-13 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
CA2425145C (en) * 2000-10-16 2011-08-30 Genentech, Inc. Methods of treatment using wisp polypeptides
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
DE60124759T2 (de) 2000-11-30 2007-03-15 The Penn State Research Foundation Dna methyl transferase inhibitoren
CN1309417C (zh) 2001-02-15 2007-04-11 王荣福 穿细胞肽在产生抗肿瘤免疫力上的用途
US20020193295A1 (en) 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US20030083261A1 (en) * 2001-04-30 2003-05-01 Hongtao Yu Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
WO2002094983A2 (en) * 2001-05-16 2002-11-28 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1480657A4 (en) 2002-02-01 2006-07-05 Intradigm Corp POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20090176660A1 (en) * 2002-03-12 2009-07-09 Seppo Yla-Herttuala Engineered Baculoviruses and Their Use
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
GB0211658D0 (en) * 2002-05-22 2002-07-03 Svanborg Catharina Novel therapies and methods of screening for therapeutic compounds
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20030125283A1 (en) * 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US9243064B2 (en) 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20070111251A1 (en) * 2003-09-02 2007-05-17 Rosania Gustavo R Chemical address tags
US20050085417A1 (en) 2003-10-16 2005-04-21 Thomas Jefferson University Compounds and methods for diagnostic imaging and therapy
WO2005056752A2 (en) * 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7655434B2 (en) * 2004-02-03 2010-02-02 The Board Of Trustees Of The Leland Stanford Junior University Live-cell biosensor polypeptides and methods of use
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US20060014712A1 (en) * 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US7604798B2 (en) * 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
US8236523B2 (en) * 2004-08-23 2012-08-07 The Johns Hopkins University Camp reporters and high throughput assays
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
EP1812030A4 (en) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF
CA2585267A1 (en) * 2004-10-29 2007-02-08 University Of Rochester Modified bacteriophage vectors and uses thereof
US20060147997A1 (en) 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
EP1828403B1 (en) 2004-12-04 2014-08-20 Los Alamos National Security, LLC Protein subcellular localization assays using split fluorescent proteins
US20060154340A1 (en) * 2005-01-07 2006-07-13 Louie Michael T Expression of potato proteinase inhibitor II in microbial hosts
JP5103748B2 (ja) 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
US7741113B2 (en) 2005-04-25 2010-06-22 Loma Linda University Cell-specific molecule and method for importing DNA into osteoblast nuclei
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2616778A1 (en) 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
US20070212332A1 (en) 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
US20070299043A1 (en) * 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
JP5043672B2 (ja) 2005-10-28 2012-10-10 田辺三菱製薬株式会社 新規細胞膜透過ペプチド
EP1951752A4 (en) * 2005-11-30 2008-12-31 Jung Moon Kim NON-ACTIVATED Wnt INHIBITOR POLYPEPTIDES AND PREPARATION METHOD THEREOF
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
WO2007069068A2 (en) 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
AU2006332193B2 (en) 2005-12-30 2012-06-28 Evonik Operations Gmbh Lactoferrin peptides useful as cell-penetrating peptides
EP1981527A4 (en) * 2006-01-27 2011-05-04 Univ Mississippi Medical Ct THERMAL TARGETED RELEASE OF MEDICAMENTS, U.A. DOXORUBICIN
CA2638807A1 (en) 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
WO2007109648A2 (en) 2006-03-20 2007-09-27 University Of Medicine And Dentistry Of New Jersey Compositions and methods for modulating store-operated calcium entry
US20100279918A1 (en) * 2006-03-20 2010-11-04 Burnham Institute For Medical Research Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
CA2657649A1 (en) 2006-07-13 2008-08-21 Burnham Institute For Medical Research Methods and compositions for targeting gc1qr/p32
HU0600578D0 (en) 2006-07-13 2006-09-28 Szilak Labor Bioinformatikai E Nuclear protein transport
WO2008033285A2 (en) 2006-09-15 2008-03-20 The Trustees Of Culumbia University In The City Of New York Delivery of double-stranded rna into the central nervous system
US7906484B2 (en) * 2006-09-21 2011-03-15 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
ES2662036T3 (es) 2007-02-28 2018-04-05 Yeda Research And Development Company Limited Secuencias que se dirigen al núcleo
WO2008127840A2 (en) * 2007-03-22 2008-10-23 University Of Iowa Research Foundation Flavivirus ns5a proteins for the treatment of hiv
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20090031733A1 (en) * 2007-07-31 2009-02-05 General Electric Company Thermotunneling refrigeration system
US8506928B2 (en) * 2007-09-07 2013-08-13 The Regents Of The University Of California Methods and compounds for targeting tissues
CN101854955B (zh) * 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
US8101388B2 (en) 2007-09-28 2012-01-24 Ut-Battelle, Llc Method and structure for extracting molecular species
AU2009234338B2 (en) * 2008-01-18 2014-07-24 Burnham Institute For Medical Research Methods and compositions related to internalizing RGD peptides
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US8753604B2 (en) 2008-12-23 2014-06-17 Sanford-Burnham Medical Research Institute Methods and compositions for synaphically-targeted treatment for cancer

Also Published As

Publication number Publication date
CN102869384A (zh) 2013-01-09
JP5906184B2 (ja) 2016-04-20
US12290569B2 (en) 2025-05-06
US20200156935A1 (en) 2020-05-21
CA2766634A1 (en) 2011-01-13
US11059718B2 (en) 2021-07-13
CN102869384B (zh) 2016-01-13
EP2445536A1 (en) 2012-05-02
US20260048133A1 (en) 2026-02-19
JP2012530787A (ja) 2012-12-06
EP2445536B1 (en) 2016-06-08
US20100322862A1 (en) 2010-12-23
WO2011005540A1 (en) 2011-01-13
JP2015044865A (ja) 2015-03-12
WO2011005540A8 (en) 2012-09-13
US20220175941A1 (en) 2022-06-09
US10370245B2 (en) 2019-08-06
KR20120048563A (ko) 2012-05-15
BRPI1015424B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
WO2011005540A8 (en) Methods and compositions using peptides and proteins with c-terminal elements
WO2009105671A3 (en) Methods and compositions related to peptides and proteins with c-terminal elements
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
WO2008079973A9 (en) Egfr binding peptides and uses thereof
WO2009126349A3 (en) Methods and compositions related to internalizing rgd peptides
CR20110470A (es) Proteínas de union a il-17
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
WO2012112690A3 (en) Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
BR112013009083A2 (pt) anticorpos humanos de oncostatin m e métodos de uso
GB201001602D0 (en) Oligopeptidic compounds and uses therof
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112012006389A2 (pt) agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo
WO2012124998A3 (ko) 바이오핀
BR112013021661A2 (pt) objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas
IN2014MN01562A (pt)
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.